MedTrace Logo

A Study of Evolocumab on Carotid Artery Atherosclerotic Plaque Morphology Prior to Carotid EndArterectomy

NCT04539223 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2022-05-02

No results posted yet for this study

Summary

This is a multicenter, randomized, open label study with blinded outcome assessment to evaluate the impact of additional/intensive LDL-cholesterol reduction with evolocumab on carotid artery atherosclerotic plaques in higher risk subjects with severe asymptomatic but vulnerable plaques.

Conditions

  • Carotid Artery Stenosis
  • Asymptomatic Carotid Artery Stenosis

Interventions

DRUG

Evolocumab

Autoinjector 1-mL deliverable volume of 140 mg/mL

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • Canadian Medical and Surgical Knowledge Translation Research Group

    lead OTHER

Principal Investigators

  • Mohammed Al-Omran, MD · Unity Health Toronto

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-28
Primary Completion
2022-04-30
Completion
2022-05-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04539223 on ClinicalTrials.gov